| 000 | 01321 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250513030717.0 | ||
| 264 | 0 | _c19940324 | |
| 008 | 199403s 0 0 eng d | ||
| 022 | _a0041-1345 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRosh, J R | |
| 245 | 0 | 0 |
_aTherapy with FK 506 in pediatric liver recipients. _h[electronic resource] |
| 260 |
_bTransplantation proceedings _cFeb 1994 |
||
| 300 |
_a152-3 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aBilirubin _xblood |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 |
_aCyclosporine _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGraft Survival |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyperkalemia _xetiology |
| 650 | 0 | 4 |
_aImmunosuppression Therapy _xadverse effects |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 |
_aInfections _xetiology |
| 650 | 0 | 4 |
_aLiver Transplantation _ximmunology |
| 650 | 0 | 4 |
_aLymphoproliferative Disorders _xetiology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aSafety |
| 650 | 0 | 4 |
_aTacrolimus _xadverse effects |
| 700 | 1 | _aSchwersenz, A H | |
| 700 | 1 | _aSchwartz, M | |
| 700 | 1 | _aMoran, V | |
| 700 | 1 | _aLeleiko, N | |
| 700 | 1 | _aLeLeiko, V M | |
| 700 | 1 | _aMiller, C M | |
| 773 | 0 |
_tTransplantation proceedings _gvol. 26 _gno. 1 _gp. 152-3 |
|
| 999 |
_c7508557 _d7508557 |
||